AMGN · 8-K · 20260804PR000124

Geographic Market Commentary

AMGEN INC · 2026-08-04 · Importance 37 · Surprise 6

U.S. product sales were $6.990 billion versus $2.547 billion in the rest of world, representing roughly 73% and 27% of total product sales, respectively. Several growth products were predominantly U.S.-driven, including Repatha at $510 million U.S. sales versus $443 million rest-of-world sales, TEPEZZA at $520 million versus $56 million, and UPLIZNA at $317 million versus $18 million. International sales were more significant for AMJEVITA/AMGEVITA, with $129 million rest-of-world sales versus $26 million in the U.S., and Aranesp, with $258 million rest-of-world sales versus $94 million in the U.S. IMDELLTRA received European Commission approval and China NMPA approval during the quarter, with commercialization in China through BeOne.